Skip to main content
Premium Trial:

Request an Annual Quote

Robert Saltmarsh, Nick Venuto

Nanogen said last week that CFO Robert Saltmarsh will retire at the end of February 2008. He will be succeeded by Nick Venuto, who currently serves as executive director of finance. Saltmarsh will continue to consult for the company through 2008.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.